The aim of this work was to improve the cytotoxic and radiosensitizing effects of gemcitabine using a gene-directed enzyme prodrug therapy approach. Murine Gl261, rat C6 and human U373 glioma cell lines were transduced with an adenoviral vector encoding the human deoxycytidine kinase gene (Ad-HudCK). Intracranial tumors were established in C57BL/6 mice and Wistar rats using either wild-type or Ad-HudCK-transduced Gl261 and C6 glioma cells. In vitro growing cells and established tumors were treated with gemcitabine and irradiation either alone or in combination. Deoxycytidine kinase overexpression substantially increased both the toxic and radiosensitizing effects of gemcitabine in each cell line, but the enhancement rate varied: it was mild in the Gl261 cells and much stronger in the C6 and U373 cells. In vivo experiments showed a mild radiosensitizing effect of dCK overexpression both in the Gl261 and C6 models. The combination of dCK overexpression, gemcitabine treatment and irradiation improved the survival rate of C6 bearing rats significantly. In conclusion, overexpression of the dCK gene can improve the cytotoxic and radiosensitizing effect of gemcitabine both in vitro and in vivo in a tumor-specific manner.
Introduction
Tumor radioresistance is a severe impediment in the success of radiotherapy in several tumor types. Malignant gliomas are among tumors considered relatively radioresistant. 1, 2 One possible way to overcome tumor radioresistance is to use a gene directed enzyme prodrug therapy (GDEPT) approach, 3 where the prodrug is a radiosensitizing chemotherapeutic agent.
Gemcitabine (2 0 ,2 0 -difluoro-2 0 -deoxycytidine) is a pyrimidine analog of deoxycytidine. In cells, gemcitabine is phosphorylated by the deoxycytidine kinase (dCK) to yield the active metabolite gemcitabine monophosphate and then by other cellular kinases to give gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). 4 The first phosphorylation reaction constitutes the rate-limiting step in the activation of gemcitabine. The diphosphate form (dFdCDP) interferes with DNA synthesis by inhibiting ribonucleotide reductase and by this way reducing the deoxynucleotide pool. The triphosphate form (dFdCTP) becomes incorporated into DNA with the subsequent addition of one further base to the DNA strand, thus halting DNA synthesis. Gemcitabine has a wide range of antitumor activity against solid tumors 5 and has been shown both in laboratory and in clinical studies to be a potent radiation sensitizer. 6, 7 It is used in combination with radiotherapy for the treatment of malignant gliomas and various brain metastases in several clinical trials. [8] [9] [10] [11] In this paper, we present a gene therapy approach to increase the toxic and radiosensitizing effect of gemcitabine in experimental glioma models. An adenovirus vector encoding the human dCK gene was introduced into glioma cell lines and the effect of the increased dCK activity was studied on gemcitabine toxicity and radiosensitization under in vitro and in vivo conditions. We show that the combination of dCK overexpression, gemcitabine treatment and irradiation act in a synergistic way, although the enhancement rate of the combination is cell-type specific.
Materials and methods
Cell lines, construction of human deoxycytidine kinase encoding adenovirus vector, in vitro transduction with adenoviral vectors Human U373 and rat C6 glioblastoma cell lines were purchased from ECACC (Salisbury, UK). The Gl261 cell line was established in our lab from the in vivo growing Gl261 tumor. [12] [13] [14] All cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum and appropriate antibiotics.
A bacterial plasmid expression vector encoding the human dCK gene was the generous gift of Dr Talianidis. 15 In the absence of appropriate restriction enzyme recognition sites the dCK insert was amplified by polymerase chain reaction using the following primers: 5 0 -TTG AATTCCACCATGGCCACCCCGCCCAAG-3 0 ; and 5 0 -A AGGATCCTCACAAAGTACTCAAAAACTC-3 0 . The primers carried an EcoRI and a BamHI restriction enzyme recognition site at their 5 0 ends, respectively. The PCR product was digested with EcoRI-BamHI and subcloned into pUC18 plasmid vector. The nucleotide sequence of the dCK insert was checked using the 'fmol DNA Sequencing System' (Promega, Madison, WI). The dCK encoding recombinant adenovirus vector (Ad-HudCK) was generated using the AdMax Adenovirus Creation Kit (Microbix Biosystems Inc., Toronto, Canada) as suggested by the supplier. Briefly, first the EcoRI-BamHI dCK fragment was cloned into the pDC516 shuttle plasmid. Then, human embryonic kidney 293 (HEK293) cells (ECACC) were co-transfected with the dCK containing shuttle plasmid and pBHGfrtDE1, 3FLP genomic plasmid using the MBS Mammalian Transfection Kit (Stratagene, La Jolla, CA). Cells were maintained in 0.33% agarose containing DMEM until lytic plaques appeared (8-10 days). Individual plaques were isolated, and tested for human dCK expression. Large-scale adenovirus vector isolation was done as described. 13 To determine transduction efficiency, Gl261, U373 and C6 cells were infected with an adenoviral vector (AdexCAlacZ) encoding the bacterial b-galactosidase (lacZ) gene at different multiplicities of infection (MOI) and lacZ activity measured as described. 13 In vitro sensitivity of glioma cell lines to dCK overexpression, gemcitabine treatment and irradiation To determine the sensitivity of the Gl261, C6 and U373 cell lines to gemcitabine, cells were seeded in 25 cm 2 tissue culture dishes at day 1 using the following cell densities: 20 Â 10 3 , 12 Â 10 3 and 6 Â 10 3 cells cm À2 for Gl261, U373 and C6 cells, respectively. The next day, cells were treated with increasing concentrations of gemcitabine. The number of surviving cells was determined 3 days later. Cells were harvested by trypsinization and the number of Trypan-blue nonstaining viable cells was counted by microscope. Surviving fraction was determined by considering the control, untreated cells 100% and calculating the percent of cells in the various treatment groups relative to the control group.
To determine sensitivity to Ad-HudCK, cells were seeded as mentioned above, and the next day cells were transduced with Ad-HudCK at increasing MOIs. Cell survival and surviving fraction were determined as described above, 3 days after the viral transduction.
To determine the combined effects of Ad-HudCK transduction, gemcitabine treatment and irradiation, cells were seeded on day 1 in 25 cm 2 ). On day 7, cell survival was determined by harvesting the cells and counting the Trypan-blue nonstaining viable cells by microscope. Surviving fraction was calculated as described above. The enhancement rate of the combination therapy was determined as follows: surviving fraction c1 Â surviving fraction c2 /100/surviving fraction combination , where c1 and c2 represent the two components of the combination therapy. For the triple combination, c1 represents surviving fraction after the combined treatment with gemcitabine and irradiation and c2 represents surviving fraction after Ad-HudCK transduction.
Preparation of cellular extracts and measurement of dCK activities Cellular extracts were prepared from wild-type or Ad-HudCK-transduced cells as described. 16 dCK activity was determined by an enzymatic reaction, where the reaction mixture contained 50 mM Tris-HCl (pH 7.6), 10 mM NaF, 5 mM ATP, 10 mM CdR, 0.1 mg ml À1 BSA, 2 mM DTT, 5 mM MgCl 2 and 0.5 mCi (22 pmol) deoxy H]cytidine (Amersham Biosciences UK Limited, Little Chalfont, Buckinghamshire, UK). Reaction was carried out in a total volume of 50 ml and was initiated by the addition of 5 ml cellular extract to 45 ml of reaction mixture, followed by incubation at 37 1C for 30 min. To stop the reaction, 30 ml of the reaction mixtures was dropped on DEAE filter disks and washed 2 Â 10 min in 1.5 mM ammonium formiate. The filters were incubated for 2 min in 200 ml of 0.5 M PCA and their radioactivity was measured in a liquid scintillation counter (LKBWallac-1217 Rackbeta, Turku, Finland). Since phosphorylation of deoxycytidine can be performed by the thymidine kinase 2 (TK2) enzyme as well, the specific dCK activity was also determined. The TK2 enzyme, which has a much better affinity to thymidine than to deoxycytidine, was saturated by the addition of 1.2 mM thymidine to the reaction mixture.
dCK activity was expressed in nmol h À1 per mg protein and was calculated as follows: dCK activity ¼ c 1 /c 2 Â dC Â 2/prot; where c 1 represents cpm sample -cpm blank , c 2 cpm maximum -cpm blank , dC total amount of labeled and unlabeled deoxycytidine in the reaction mixture applied on the filter paper (expressed in nmol ml À1 ); 2 represents a constant to correct enzyme activity for 60 min; prot represents total protein amount present in the reaction mixture applied on the filter paper (expressed in mg ml À1 ).
Animal studies
The Gl261 murine and the C6 rat glioma models were used. For intracranial tumor implantation of C6 rat glioma cells, 5-to 6-week-old male Wistar rats were anesthetized and placed in a stereotactic apparatus. The scalp was opened and a burr hole was made at bregma and 2 mm to the right of the cranial midline suture. Injection was carried out with a 50 ml Hamilton syringe and the needle was inserted to a depth of 5.0 mm below the dura. Tumor inoculation was performed either with wild-type or with Ad-HudCK-transduced C6 cells. Five microliters of cell suspensions, containing 1.5 Â 10 5 C6 cells in Hank's balanced salt solution, was injected over a period of 5 min. Viral transduction of C6 cells was carried out in vitro at 300 MOI 24 h before tumor implantation. Three days after tumor implantation, rats were treated with intraperitoneal injection of 60 mg kg À1 body weight gemcitabine, and 24 h later the head of the anesthetized rats was irradiated with 4 Gy X rays (THX-250 therapeutic X-ray source; Medicor, Budapest, Hungary; dose rate: 1.003 Gy min À1 ). A lead tube shielded the other parts of the body to protect from radiation.
For intracranial tumor implantation of Gl261 cells, male C57BL/6 mice (6-to 8-week-olds) were used. Intracranial implantation of tumor cells, treatment and follow-up of the animals was carried out similarly to rats, with the following exceptions: 2 Â 10 4 Gl261 cells were injected in a total volume of 3 ml to a depth of 3 mm below the dura over a period of 3 min; in vitro viral transduction of Gl261 cells with Ad-HudCK was carried out with 20 MOI. Animals were killed when they were moribund or 100 days after tumor cell inoculation and were carefully autopsied.
Animal studies were carried out in accordance with the Hungarian regulations under the permission of the Institutional and National Body of Animal Care and Testing. All treatment groups consisted of 4-5 animals and experiments were repeated three times.
Analysis of survival data was performed using the Kaplan-Meier method. Comparisons of survival curves were carried out with the Kaplan-Meier log-rank test.
Statistical significance of data was tested by Student's t-test.
Results

Deoxycytidine kinase activity and gemcitabine sensitivity of nontransduced glioma cell lines
The relationship between basal dCK activity and gemcitabine sensitivity was investigated in three well-characterized and frequently used glioma cell lines (mouse Gl261, human U373, rat C6). Both the total and specific dCK activities of the cells were determined and strong differences were found among the cell lines. Gl261 cells had the highest total and specific dCK activity, while enzyme activities in U373 and C6 cells were lower. The biggest difference in the specific compared to total dCK activity was observed in C6 cells ( Table 1) .
The in vitro gemcitabine sensitivity of the three cell lines was compared: Gl261 cells were the most sensitive and U373 cells the most resistant ( Figure 1 ). The IC 50 values were 11, 39 and 282 nM for the Gl261, C6 and U373 cells, respectively.
Deoxycytidine kinase activity of Ad-HudCK-transduced cells, the toxic effect of dCK overexpression under in vitro conditions First, the transduction efficiency of adenoviral vectors was investigated. Gl261, U373 and C6 cells were infected with AdexCAlacZ at different MOI and LacZ activity À1 protein), probably because adenoviral transduction efficiencies were close to 100%. In Gl261 cells, enzyme activities at transduction rates higher than 100 MOI could not be determined due to the high toxicity of Ad-HudCK on these cells (see later). The highest relative increase in dCK level was detected in C6 cells, where enzyme activity at 200-300 MOI was about 140-fold higher than the basal dCK activity and reached a plateau at around 8.3 nmol h À1 per mg protein. During the transduction experiments with Ad-HudCK, we noted that high dCK levels might be toxic for the cells. Therefore, the potential toxic effects were thoroughly investigated. Cells were infected with Ad-HudCK at increasing MOI and survival followed. A strong cytotoxic effect of dCK overexpression following Ad-HudCK transduction was detected in Gl261 and U373 cells. The C6 rat glioma cell line tolerated high dCK levels well, since only mild cytotoxicity was detected even at 300 MOI ( Table 2) .
Sensitivity of Ad-HudCK-transduced cells to gemcitabine and radiation under in vitro conditions
We investigated whether the introduction of the dCK gene into Gl261, C6 and U373 glioma cells could increase the direct cytotoxic and radiosensitizing effect of gemcitabine. In these experiments, the different sensitivity of the cell lines toward gemcitabine treatment and adenoviral transduction was taken into consideration. Cells were treated with gemcitabine concentrations, which had very similar cytotoxic effects on their own, and were only moderately toxic to the nontransduced cells (60-80% survival; Figure 2 ). It was important to use drug concentrations that were only moderately toxic, otherwise the enhancement in the cytotoxic or radiosensitizing effect would have been difficult to evaluate. Thus, the following gemcitabine concentrations were used: 5 nM for the GL261 cells, 25 nM for the C6 cells and 250 nM for the U373 cells. When choosing the suitable viral transduction rates, two conditions should be fulfilled: to get similar transduction efficiencies and dCK activities in all three cell lines. Thus, the following transduction rates were used: 20 MOI for the Gl261 cells, 100 MOI for the U373 cells and 300 MOI for the C6 cells. These adenoviral transduction rates (MOI) gave nearly identical transduction efficiencies (65-75%). The dCK activities for the C6 and U373 cells were identical (around 8 nmol h À1 per mg protein; see Table 1 ). In the case of the Gl261 cells, due to the toxicity of the Ad-HudCK construct, we had to use a suboptimal transduction rate (20 MOI) , where the enzyme activity was only half of the other two cell lines (around 4 nmol h À1 per mg protein; Table 1 ). In the experiments combined with irradiation, cells were treated with 4 Gy 60 Co-g-radiation (35-60% survival in nontransduced cells; Figure 2 ).
Deoxycytidine kinase overexpression had different toxic effects: about 35, 60 and 80% survival in Gl261, U373 and C6 cells, respectively. Increased dCK activity had no radiosensitizing effect in the studied cell lines under in vitro circumstances (Figure 2 ).
In the absence of dCK overexpression, gemcitabine had a minor, but significant radiosensitizing effect in Gl261 cells (Figure 2a) . In U373 and C6 cells, the combination of gemcitabine treatment and irradiation had only additive effects (Figures 2b and c) .
Deoxycytidine kinase overexpression enhanced gemcitabine toxicity in each investigated cell line, but the enhancement rate varied. The most modest effect was detected in Gl261 cells, where dCK overexpression led to Abbreviations: Ad-HudCK, adenoviral vector encoding the human deoxycytidine kinase gene; MOI, multiplicities of infection; ND, not determined. Cells were transduced with Ad-HudCK at increasing multiplicities of infection, cell survival and surviving fraction was determined as described in Materials and methods. Data represent the mean values of three independent experiments ± s.d. dCK overexpression improved the radiosensitizing effect of gemcitabine too, but the rate of radiosensitization was again different in the studied cell lines: it was mild in Gl261 (1.25-fold) and strong in C6 and U373 cells (2.3-and 3.6-fold, respectively; Figure 2 ).
The effect of deoxycytidine kinase overexpression in vivo
The murine Gl261 and the rat C6 intracranial tumor models were used to investigate the in vivo effects of dCK overexpression. Intracranial tumors were established by transplanting either wild-type or dCK-overexpressing tumor cells. To create dCK-overexpressing cells, in vitro growing Gl261 and C6 cells were transduced with Ad-HudCK (20 MOI for Gl261 and 300 MOI for C6) 1 day before tumor transplantation. These MOIs were selected for transduction because they increased intracellular dCK levels substantially. Animals were treated with gemcitabine and local tumor irradiation as described in Materials and methods. Overexpression of the dCK gene had no effect on in vivo tumor growth, neither in the Gl261 nor in the C6 model. Gemcitabine treatment alone had minor effect on tumor growth both in the Gl261 and C6 models and dCK overexpression could not improve this effect. In both animal models, dCK overexpression increased the antitumor effect of local tumor irradiation: about 25 and 28% survival rate for the Gl261 and C6 models, respectively (Figures 3 and 4) . In the Gl261 model, the combination of gemcitabine treatment and tumor irradiation led to about 20% survival rate and to a 30% increase in the animal life Figure 3 Survival of glioma bearing mice after gemcitabine treatment and local tumor irradiation. Gliomas were induced in mice by intracranial transplantation of either wild-type (wt) Gl261 cells (a) or Gl261 cells transduced with the Ad-HudCK (dCK) vector (b). Mice were treated with gemcitabine (gemc) and local tumor irradiation (irr) as described in Materials and methods. Survival curves represent the pooled data of three independent experiments. Po0.4300 for the group treated with Ad-HudCK, gemcitabine and local irradiation versus the group treated with gemcitabine and irradiation.
Radiosensitizing gene therapy of gliomas T Szatmári et al span and this was slightly improved in the dCK/ gemcitabine/radiation-treated group (25% survival and 43% increase in life span, Figures 3a and b, Table 3 ), but the differences were not statistically significant (Po0.43).
In the rat C6 model, the combined treatment with gemcitabine and tumor irradiation in the absence of dCK overexpression resulted in 16% survival and practically no increase in the animal life span (Figure 4a , Table 3 ). Significantly improved (Po0.0162) survival rate (nearly 70%) and animal life span (about 41%) were detected when gemcitabine treatment and irradiation was combined with dCK overexpression (Figure 4b, Table 3 ).
Our data suggest that dCK overexpression, apart from its own minor in vivo radiosensitizing effect, can substantially improve the combined effect of gemcitabine treatment and local tumor irradiation.
Discussion
The combined effect of dCK overexpression, gemcitabine treatment and irradiation was investigated in three frequently used glioma cell lines. Special emphasize was placed on the level of gemcitabine radiosensitization by dCK overexpression in these tumor models.
Basal dCK expression was found to be low in all three glioma cell lines. An interesting finding was the great variation in the basal dCK activity of the Gl261, U373 and C6 cell lines. About 16-fold difference was found between the specific dCK activity of Gl261 and C6 cells. Low dCK levels were formerly reported in other brain tumor cells, as well. 18 Sensitivity to gemcitabine also varied broadly in the investigated cell lines. While Gl261 cells were very sensitive to low gemcitabine concentrations, U373 cells were relatively resistant. Several reports Figure 4 Survival of glioma bearing rats after gemcitabine treatment and local irradiation. Gliomas were induced in rats by intracranial transplantation of either wild-type (wt) C6 cells (a) or C6 cells transduced with the Ad-HudCK (dCK) vector (b). Rats were treated with gemcitabine (gemc) and local tumor irradiation (irr). Survival curves represent the pooled data of three independent experiments. Po0.0162 for the group treated with Ad-HudCK, gemcitabine and local irradiation versus the group treated with gemcitabine and irradiation.
Radiosensitizing gene therapy of gliomas
T Szatmári et al in the literature suggest that basal dCK level is the direct determinant of cellular gemcitabine sensitivity. [19] [20] [21] Other data, in contrary, show that dCK level is not the sole determinant of gemcitabine sensitivity of the cells. It is suggested that other enzymes, such as ribonucleotide reductase or deoxycytidine deaminase, which have an important role in regulating the intracellular deoxyribonucleotide pool and indirectly also take part in the intracellular metabolism of gemcitabine, can strongly influence gemcitabine sensitivity. 22, 23 In the case of the Gl261 and U373 cells, we could detect a rather direct relationship between basal dCK activity and gemcitabine sensitivity. However, a discrepancy between dCK expression and gemcitabine sensitivity was found in C6 cells, where the basal dCK activity was very low, still the cells were relatively sensitive to gemcitabine ( Figure 1 and Table 1 ). We should note that the biggest difference between total and specific dCK activity was found in C6 cells, which indicates the presence of an increased mitochondrial TK2 activity in C6 cells. It was shown that apart from the dCK, the TK2 enzyme can also phosphorylate gemcitabine. 24 Thus, the increased TK2 enzyme activity in the C6 cells could compensate for the very low basal dCK levels and might explain the discrepancy between the relatively high gemcitabine sensitivity and the low basal dCK activity of the cell line. This hypothesis is also supported by the findings of Sanda et al., 25 who showed that gemcitabine, which was phosphorylated in the mitochondria, could incorporate into mitochondrial DNA, which would lead to apoptosis. Still, our experiments clearly proved that adenoviral transfer of the dCK gene into C6 cells substantially increased dCK enzyme activity and improved the activation of gemcitabine, which led to strongly enhanced cytotoxic effects.
The great intercellular variations in gemcitabine sensitivity might be also explained by the multiple mechanisms of action of gemcitabine. Since phosphorylation of the drug by dCK is only one mechanism of drug cytotoxicity, other mechanisms such as incorporation into RNA, 26 inhibition of ribonucleotide reductase 27 and DNA polymerase 28 might counteract the importance of low dCK levels in gemcitabine cytotoxicity.
An adenoviral construct, encoding the human dCK enzyme, was used to increase dCK activities in the studied cell lines and in animal tumor models. Some previous studies showed that there might be species-specific differences between mice and humans in the efficiency of gemcitabine phosphorylation by dCK (the murine dCK can phosphorylate gemcitabine and other nucleoside analogs less efficiently than the human enzyme).
29-31
Still, we decided to use the human enzyme in all investigated cell lines and tumor models because the extrapolation of the experimental results for the treatment of human tumors would be easier. Although the human dCK enzyme was heterologous for Gl261 and C6 cells, no major differences were noted in the enzyme activities compared to U373 cells (around 8 nmol h À1 per mg protein at high MOI; see Table 1 ).
We showed that dCK overproduction by transduction of the cell lines with the Ad-HudCK construct was toxic for Gl261 and U373 cells, but not for C6 rat cells. The toxic effect of the adenovirus vector itself can be excluded, since we did not detect signs of cytotoxicity when cells were transduced with the adenovirus vector encoding the LacZ gene. Formerly, we used a panel of adenovirus vector constructs encoding for various cytokine and drugsensitizing genes to transduce the Gl261 cell line, but none of them produced cytotoxic effects comparable to the Ad-HudCK construct.
12-14 Manome et al. 32 used an adenoviral vector to transfer the dCK gene into 9L cells, but the authors do not discuss the effect of the dCK encoding vector on cell survival. There are relatively few other reports in the literature describing the effect of dCK overproduction in various cells or tumor models, but none of them utilized the cell lines discussed in the present paper. Hapke et al. 33 applied a retroviral vector to transfer the dCK gene into MCF-7, HT-29 and H1437 cell lines. Blackstock et al. 34 used the same retroviral construct in HT-29 cells. Beause´jour et al. 35 utilized another retroviral construct to transfect the human dCK gene into human A549 lung carcinoma and murine 36 transduced the Colon 26 mouse colon carcinoma and 9L rat gliosarcoma cell lines with another human dCK encoding retroviral vector. None of these authors mentioned signs of increased toxicity in vitro, but one should take into account that much higher dCK levels can be achieved with adenoviral vectors than with retroviruses. We think that the strong dCK overexpression might produce severe perturbations in the nucleotide pool and metabolism in Gl261 and U373 cells, which could lead to cellular death. Further investigations are necessary to reveal the exact mechanism behind.
The in vitro radiosensitizing effect of gemcitabine treatment was assessed next. The mechanism of gemcitabine radiosensitization is not fully understood. Most studies show that gemcitabine treatment produces a complete inhibition of DNA synthesis, a depletion of dATP pool and an accumulation of cells in early S phase, which can contribute to misrepair of DNA damage after radiation. Other mechanisms, such as inhibition of chromosome repair after irradiation, might also effectively contribute to radiosensitization. [37] [38] [39] [40] Gemcitabine was administered 24 h before irradiation. This scheduling was chosen, because our preliminary experiments (G Sa´fra´ny and S De´saknai, personal communication, 2005), in concordance with other reports in the literature, confirmed that optimal radiosensitization, both in vitro and in vivo, is achieved if the drug is administered 24-72 h prior to irradiation. 39, 41 Gemcitabine had a significant radiosensitizing effect in Gl261 cells; the effect was additive in the other two cell lines. This correlates well with the fact that Gl261 cells had the highest basal dCK activity and were the most sensitive to gemcitabine. It is also in concordance with other data in the literature which state that gemcitabine radiosensitization is more pronounced in cells with high basal dCK activity. 42 We should note, that Pauwels et al. 43 recently reported that dCK activity weakly correlated to gemcitabine radiosensitization. Besides the high basal dCK level, another possible explanation for the radiosensitizing effect of gemcitabine is that irradiation itself can induce dCK activity in Gl261 cells by twofold (G Sa´fra´ny and S De´saknai, personal communication, 2005), which, in turn might further improve gemcitabine metabolism and amplify its toxic effect. Formerly, Csapo et al. 44 has already described that radiation is a strong dCK activating agent in human lymphocytes. They presumed a two-step mechanism for the radiation-responsive induction of dCK activity: the early dCK activation should be due to post-translational changes rather than modifications in the protein content, while long-term dCK activation was ascribed to adaptive transcriptional changes and elevation in the protein levels, as well.
Several research groups investigated the effect of dCK overexpression on the toxicity of various nucleoside analogs in vitro. Most of these groups agree that elevation of the dCK enzyme activity leads to an increase in the drug toxicity, as well. Hapke et al. 33 investigated the toxicity of three nucleoside analogs after retroviral transfer of dCK into various tumor cell lines. They showed a strong correlation between dCK activity and 1-b-D-arabinofuranosylcytosine (AraC), 2-chloro-2 0 -deoxyadenosine (CdA) or 2-fluoro-9-b-D-arabinofuranosyladenine (FAraA) toxicity, but a lesser level of correlation existed between dCK activity and gemcitabine toxicity. Beause´jour and co-workers 35 reported that dCK overexpression could increase AraC and 5-aza-2 0 -deoxycytidine (5-aza-CdR) toxicity in human A-549 and murine NIH 3T3 cell lines, but led to an unexpected drug resistance against gemcitabine. Our results show that increased dCK activity upon adenoviral transfer of the gene could sensitize cells to gemcitabine. Deoxycytidine overexpression enhanced gemcitabine toxicity in all three investigated cell lines, but the enhancement rate varied. It was more pronounced in the C6 and U373 cells, and less effective in the Gl261 cells. Moreover, we also showed that dCK overexpression could improve not only the toxic, but also the radiosensitizing effect of gemcitabine. Strong enhancement was found in C6 and U373 cells, and more modest effect was detected in Gl261 cells. It cannot be excluded that the reduced sensitization of dCK in the Gl261 cells was due to the suboptimal transduction rate of these cells with Ad-HudCK.
Finally, we evaluated the combined in vivo therapeutic effect of dCK overexpression, gemcitabine treatment and irradiation in the Gl261 and C6 models. Few reports exist in the literature that used dCK gene transfer to improve therapeutic responses to nucleoside analogs. One of the earliest reports is that by Manome et al. 32 who showed that viral vector transduction of dCK sensitizes 9L cells to the cytotoxic effects of cytosine arabinoside (AraC) in vitro and in vivo. They used both a retroviral and an adenoviral dCK construct. They showed significantly improved survival rates when tumors were treated with dCK gene transfer and AraC. In another study, Blackstock et al. 34 used a retrovirus vector to introduce the dCK gene in HT29 cells. They showed a substantial regression in the growth rate of HT29 xenografts transduced with dCK encoding vector and treated with gemcitabine. They concluded that increased dCK expression enhanced gemcitabine accumulation and prolonged elimination, which, in turn, could augment in vivo tumor responses to gemcitabine. Vernejoul et al. 45 generated a fusion gene combining dCK and uridine monophosphate kinase and used it in a suicide gene therapy approach together with gemcitabine to treat human pancreatic cancer established in hamsters. They showed that the fusion gene could efficiently sensitize pancreatic cancer cells to gemcitabine and they also could prove a substantial bystander effect, which was due to apoptosis. Our data show that the therapeutic effects of the combined treatment modality were much lower in the Gl261 than in the C6 model. This is in concordance with the in vitro findings. Although the in vitro data showed that dCK overexpression was toxic for the Gl261 cells, in the in vivo setting there was practically no difference in the survival of mice transplanted with wild-type or dCKoverexpressing tumor cells. An interesting finding was the modest, but well detectable radiosensitizing effect of dCK overexpression itself. Gemcitabine alone had no significant therapeutic effect in any of the two tumor models. Despite this, a strong radiosensitizing effect of gemcitabine was demonstrated in the dCK-overexpressing C6 cells, which was translated into a significant improvement in survival. These results strengthen previous reports that gemcitabine is a powerful radiation sensitizer even at doses well below those used to produce cytotoxicity. 37, 41, 46 We should note, however, that in the in vivo experiments Ad-HudCK pre-transduced tumor cells were used (about 65-75% of the cells contained the virus at the time of tumor transplantation). This experimental setting reflects an ideal condition, which can seldom be reached in the clinic, where the therapeutic gene should be delivered by direct intratumoral injection of the virus vector.
In conclusion, we demonstrated that the toxicity and the radiosensitizing effect of gemcitabine can be significantly improved by the overexpression of the dCK enzyme in tumor cells by the GDEPT approach. There might be several ways to further improve the efficiency of this protocol. One possibility is the development of viral vectors, which can either replicate in a tumor-specific manner or the expression of the therapeutic gene is driven by tumor specific promoters. 3 Further improvement might be the design of dCK mutants, which have an increased efficiency toward gemcitabine phosphorylation. 47 
